Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB10 in Healthy Participants and Patients With Hemophilia A
NCT07847697Phase 1Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, randomised trial in hemophilia A (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Dose-Limiting Toxicity at 6 weeks, Treatment-Emergent Adverse Events at 25 weeks and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07847697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847697.